Nov 27, 2018
Company Announces Results from Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) Oral Solution CV in Patients with Dravet Syndrome
Nov 19, 2018
Greenwich Biosciences to Present New Data on FDA-approved EPIDIOLEX® (cannabidiol) Oral Solution CV at the American Epilepsy Society Annual Meeting
Nov 1, 2018
EPIDIOLEX® (cannabidiol) Oral Solution – the First FDA-approved Plant-derived Cannabinoid Medicine – Now Available by Prescription in the U.S.
Sep 27, 2018
Greenwich Biosciences Announces the DEA has Rescheduled EPIDIOLEX® (cannabidiol) Oral Solution to Schedule V
Jun 25, 2018
Greenwich Biosciences Announces FDA Approval of Epidiolex® (cannabidiol) Oral Solution – the First Plant-derived Cannabinoid Prescription Medicine
Apr 13, 2018
Greenwich Biosciences to Present Data on Epidiolex® (cannabidiol oral solution) at the 2018 American Academy of Neurology Annual Meeting
Feb 13, 2018
Greenwich Partners With Childhood Neurology Foundation and Indiana University to Improve Communication Between Neurologists and Families of Children Living With Epilepsy
Jan 24, 2018
The Lancet Publishes a Landmark Study of Our Investigational Drug, Epidiolex® (cannabidiol)
Jan 4, 2018
The Food and Drug Administration (FDA) Accepts the NDA Filing of Epidiolex® (cannabidiol) for Priority Review

Greenwich Biosciences, Inc. is the US subsidiary of GW Pharmaceuticals plc. For general corporate information, please click here.